

## **Micromet Launches Phase I Trial Combining Its Antibody MT201 with Docetaxel for the Treatment of Breast Cancer**

April 27, 2005, Munich, -- Micromet AG, a private biopharmaceutical company, has initiated a phase I trial to test the combination of its human pan-carcinoma antibody MT201 (adecatumumab) with Taxotere(r) (docetaxel) in patients suffering from relapsed or primary refractory breast cancer. The study will evaluate the safety and tolerability of a combination of the two drugs. It will enroll 12 patients, and will be conducted in Austria and Germany.

MT201 is currently also being tested in two international phase II monotherapy studies for the treatment of prostate and metastatic breast cancer. A previous phase I monotherapy study demonstrated an excellent safety profile. The candidate is being co-developed with Serono.

"We do believe that the combination of our human antibody with chemotherapeutics such as Taxotere(r) has the potential to enhance anti-tumor activity of the single agents. Chemotherapeutics primarily act against dividing cells, while MT201 has the potential to also eliminate cancer cells that are momentarily dormant," comments Christian Itin, Micromet's CEO.

The combination trial fully complies with the stringent quality requirements under the new European Clinical Trials Directive.

MT201 is a fully human antibody targeting the epithelial adhesion molecule Ep-CAM, which is overexpressed with high frequency on most human carcinomas including breast, prostate, colon, lung, stomach, pancreas, head & neck and ovary cancer.

###

### **Contact Information**

*Media:* Evelyn Wolf, Phone: +49 89 895277-220, Email: [evelyn.wolf@micromet.de](mailto:evelyn.wolf@micromet.de)

*Investors:* Ines-Regina Buth, Phone: +49 89 895277-221, Email: [ines-regina.buth@micromet.de](mailto:ines-regina.buth@micromet.de)

Micromet AG, Staffelseestr. 2, 81477 Munich, Germany

### **About Micromet AG**

Micromet AG, a private Munich-based biotechnology company, puts novel concepts in immunotherapy to work. Using proprietary technologies, the Company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. Two candidates are currently in clinical trials. The Company has established a powerful drug development platform based on its BiTE(tm) technology ("Bispecific T cell engagers"), a unique drug format that leverages the outstanding cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. In addition, Micromet is exploiting the potential of SCAs (single-chain antibodies) for the development of novel drugs under a multiyear strategic collaboration with Enzon Inc. Micromet has integrated infrastructure and expertise in all disciplines of drug design and development. The Company has attracted both top-tier life-science investors and corporate partners such as MedImmune, Inc., Enzon Pharmaceuticals, Inc. and Serono. For further information, please visit the Company's web site at [www.micromet.de](http://www.micromet.de).